Nabi Biopharmaceuticals launches its second unit, Nabi Pharmaceuticals
Nabi Biopharmaceuticals recently launched its second strategic business unit, Nabi Pharmaceuticals. The first unit launched was Nabi Biologics. Nabi Pharmaceuticals will be responsible for overseeing NicVAX(R) (Nicotine Conjugate Vaccine) and StaphVAX(R) (Staphylococcus aureus Polysaccharide Conjugate Vaccine) development programs, as well as for continuing with development requirements following the sale of PhosLo(R) (calcium acetate). According to Dr. Leslie Hudson, interim president and chief executive officer of Nabi Biopharmaceuticals, by developing new units supported by Banc of America Securities, Nabi Pharmaceuticals has secured a partner for its NicVAX and StaphVAX programs. Moreover, to facilitate strategic alternatives and partnership processes and to optimize the value of Nabi products, the company has appointed Dr. Matthew W. Kalnik to its board, Hudson also stated. Nabi Biopharmaceutical's product portfolio contains the successful Nabi-HB(R) [Hepatitis B Immune Globulin (Human)].
Panacea Pharmaceuticals appoints Fuller as vice president, product development and Wood as director, clinical laboratory services
Panacea Pharmaceuticals, Inc. has appointed Steven A. Fuller, Ph.D., as vice president, product development and Billie Jo Wood as director, clinical laboratory services. In his new position, Dr. Fuller will be responsible for product development, validation, process development, and manufacturing for the company's therapeutic and diagnostic products. He will be working in association with the staff in regulatory affairs and clinical development. Wood will be overseeing Panacea Laboratories, a division of Panacea Pharmaceuticals, and his duties will include testing patient samples, marketing the availability of the company's diagnostic tests, and assuring adherence to regulatory requirements. A privately held biopharmaceutical company, Panacea Pharmaceuticals, Inc. primarily focuses on development and commercialization of therapeutics and diagnostics for diseases that demand clinical attention.
Biotechnology Industry Organization to host a conference September 24-26, 2007
In an effort to network and explore funding and collaboration opportunities for bioscience, biofuel, and medical device companies, the Biotechnology Industry Organization (BIO), is organizing a conference to be held on September 24-26, 2007 at the Hyatt Regency Milwaukee. The conference is the only venture conference organized in the Midwest for companies and their products to get the attention and opinions of the professional community. Life-science investors, CEOs, and business-development executives in Milwaukee, WI, will be participate in the conference. The BIO Mid-America VentureForum will enable attendees to conduct private meetings with investors and potential partners and to satisfy their requirements in terms of specific pipeline or technology needs. Moreover, the on and off-site database tools will assist companies in clinching potential partnering opportunities. Partners for the 2007 conference include Wisconsin Biotechnology, Medical Device Association, BioOhio, Colorado Bioscience Association, Illinois Biotechnology Industry Organization, Missouri Biotechnology Association, MichBio, LifeScience Alley, Iowa Biotechnology Association, and the Indiana Health Industry Forum.
